Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences

Rhea-AI Summary

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) announced its participation in several investor conferences in March 2021. Key events include the H.C. Wainwright Global Life Sciences Conference on March 9, Roth Capital Partners Annual Conference on March 15, and Oppenheimer & Co. 31st Annual Healthcare Conference on March 16, followed by the Maxim Group Emerging Growth Virtual Conference on March 17. Webcasts will be available on-demand on the company’s website, where replays can be accessed for 90 days.

Antibe is developing safer therapies using its hydrogen sulfide platform, targeting conditions like osteoarthritis and inflammatory bowel disease.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions, today announced its participation in the following investor conferences in March:

H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 am (Eastern Time) a pre-recorded company presentation will become available for on-demand viewing.
Roth Capital Partners Annual Conference, Live fireside chat on Monday, March 15, 2021, at 9:00 am (Eastern Time).
Oppenheimer & Co. 31^st Annual Healthcare Conference, Company presentation on Tuesday, March 16, 2021 at 9:20 am (Eastern Time).
Maxim Group Emerging Growth Virtual Conference on Wednesday, March 17, 2021 at 10:00 am (Eastern Time) a pre-recorded company presentation will become available for on-demand viewing.

A link to the webcast of each event will be available on the News and Events section of the Company’s website at antibethera.com. Following the events, a replay of the webcasts will be available on the website for 90 days.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. Antibe’s current pipeline includes three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005297/en/

FAQ

What investor conferences is Antibe Therapeutics participating in March 2021?

Antibe Therapeutics is participating in the H.C. Wainwright Global Life Sciences Conference on March 9, Roth Capital Partners Annual Conference on March 15, Oppenheimer & Co. 31st Annual Healthcare Conference on March 16, and Maxim Group Emerging Growth Virtual Conference on March 17.

When will the webcasts of Antibe's conference presentations be available?

Webcasts of Antibe Therapeutics' presentations will be available for on-demand viewing on their website, with replays accessible for 90 days following the events.

What is the focus of Antibe Therapeutics' drug development?

Antibe Therapeutics focuses on developing safer therapies to address inflammation and gastrointestinal issues associated with traditional pain medications, particularly for osteoarthritis and inflammatory bowel disease.

What is the lead drug of Antibe Therapeutics and its current status?

Antibe Therapeutics' lead drug, otenaproxesul, is entering Phase III trials for osteoarthritis pain.

What is the unique platform that Antibe Therapeutics is using for its drug development?

Antibe Therapeutics is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies.